Oxurion General Meeting Postponed

Leuven, Belgium – Oxurion NV, the Belgian biopharmaceutical company listed on Euronext Brussels under the symbol OXUR, has announced the postponement of its Annual General Meeting. Originally scheduled, this meeting is now scheduled for May 13, 2025. The reason given is the incomplete completion of the annual accounts due to administrative reasons.

Oxurion specializes in the development of innovative ophthalmic therapies to treat retinal diseases. Located in Leuven, it continues to make advances in this field.

The press release also addressed forward-looking statements, which are subject to various risks and uncertainties, and clarified that this did not constitute an offer to sell securities.